| 초록 |
Objectives: Tenofovir disoproxil fumarate (TDF)–based antiretroviral therapy (ART) is widely used in people living with HIV, but concerns remain regarding its long‑term nephrotoxicity in real‑world settings. We evaluated the association between different TDF‑based regimens, treatment duration, and kidney function in an HIV cohort from Indonesia. Methods: We conducted a cross-sectional study of 173 adults living with HIV receiving TDF-based ART at a single center. ART regimens were grouped as TDF/3TC/DTG, TDF/3TC/EFV, and other TDF-based regimens. Kidney function was assessed using serum urea and creatinine, and eGFR calculated by CKD-EPI. eGFR was categorized using KDIGO-based strata. Differences in categorical eGFR distribution across ART regimen groups and across concomitant medication burden (1 vs ≥8 non-ART drugs) were assessed using chi-square tests. Differences in continuous kidney parameters (urea and creatinine) across ART regimens were assessed using appropriate group-comparison tests based on data distribution (ANOVA if normally distributed; otherwise Kruskal-Wallis). Correlations between ART duration and kidney parameters (urea, creatinine, and eGFR) were evaluated using Spearman’s rank correlation. Statistical significance was set at p<0.05. Results: The most common regimens were TDF/3TC/DTG (67.6%) and TDF/3TC/EFV (28.9%); the remaining participants received other TDF-based regimens (3.5%). Based on KDIGO-based eGFR categories, 38.2% had normal/high eGFR, 43.4% had mildly decreased eGFR, 3.4% had moderately-to-severely decreased eGFR, and 15.0% were classified as kidney failure. There were no statistically significant differences in serum urea, creatinine, or eGFR category distribution across ART regimen groups (all p>0.05). Concomitant medication burden (1 vs ≥8 non-ART drugs) was not associated with eGFR category distribution (p>0.05). ART duration showed no significant correlation with serum urea, creatinine, or eGFR (all p>0.19). Conclusion: In this HIV cohort on TDF-based regimens, reduced eGFR was common but unrelated to regimen type or treatment duration, suggesting renal risk depends more on patient vulnerability, emphasizing routine monitoring and further study of ART-related nephrotoxicity. |